Skip to main content
. 2022 Mar 7;13:806737. doi: 10.3389/fphar.2022.806737

FIGURE 1.

FIGURE 1

Kaplan-Meier curves for PFS of afatinib for distinct HER2 ex20ins variants G776delinsVC and A775_G776insYVMA in first-line (A) and second-line setting (B). Kaplan-Meier curves for PFS of pyrotinib vs. afatinib among overall ex20ins patients as first-line (C) and second-line therapy (D).